Transforming Cancer Care with Immunotherapy
Aspirus Cancer Care now offering BiTE Therapy
7/29/2024
Dr. Thomas Oliver, Oncologist and Hematologist for Aspirus Cancer Care
Aspirus Cancer Care
is offering a new type of immunotherapy treatment that has emerged as one of
the most promising strategies for battling certain types of cancer including
Lymphoma, Acute Lymphocytic Leukemia (ALL), multiple myeloma, and small-cell
lung cancer.
Bispecific T-cell
Engager (BiTE) Therapy is a type of immunotherapy that triggers a patient’s own
immune system to attack cancer cells. BiTE Therapy essentially directs certain
immune cells, called T-cells, to attack and kill cancer cells.
Dr. Thomas Oliver,
an Oncologist and Hematologist for Aspirus Cancer Care, explains how this
innovative treatment works. “BiTEs offer targeted therapy by using antibodies
to connect cancer cells and immune T-cells. The T-cell’s antitumor functions
are stimulated and molecules that poke holes in the cancer cells are released,”
Oliver says.
One of many benefits
of BiTEs is the ability to target tumors directly while minimizing damage to
healthy tissues. “While patients undergoing BiTE Therapy may experience side
effects, they differ from the side effects patients typically have to endure with
chemotherapy,” continues Oliver.
Patients undergoing
treatment for Lymphoma, ALL, multiple myeloma, and small-cell lung cancer
should discuss with their provider whether BiTE Therapy is right for them.
Aspirus Cancer Care
includes a comprehensive team of experts to compassionately care for cancer
patients along their entire treatment journey, including nurse navigators,
pharmacists, social workers, dieticians, and more.
To learn more, visit
aspirus.org/cancer.
Back to all Posts